Today, Incyte Corp. (INCY) Stock Rating Reaffirm by Jefferies Group

Today, Incyte Corp. (INCY) Stock Rating Reaffirm by Jefferies Group
Incyte Corp. (NASDAQ:INCY)‘s stock had its “buy” rating reaffirmed by Jefferies Group in a research note issued on Tuesday.

Other research analysts also recently issued research reports about the company. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Incyte Corp. in a research note on Wednesday, September 28th. SunTrust Banks Inc. started coverage on Incyte Corp. in a research note on Friday, August 5th. They set a “buy” rating and a $105.00 price target for the company. Piper Jaffray Cos. reaffirmed a “buy” rating and set a $102.00 price target (up previously from $76.00) on shares of Incyte Corp. in a research note on Monday, August 1st. Zacks Investment Research raised Incyte Corp. from a “hold” rating to a “buy” rating and set a $94.00 price target for the company in a research note on Tuesday, July 19th. Finally, Leerink Swann reaffirmed a “buy” rating on shares of Incyte Corp. in a research note on Monday, July 18th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twenty have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $103.08.

Incyte Corp. (NASDAQ:INCY) opened at 107.73 on Tuesday. Incyte Corp. has a 52 week low of $55.00 and a 52 week high of $118.49. The firm’s 50-day moving average is $94.54 and its 200 day moving average is $85.83. The stock has a market cap of $20.29 billion, a price-to-earnings ratio of 144.80 and a beta of 0.79.

In other news, EVP Paula J. Swain sold 20,000 shares of the business’s stock in a transaction dated Friday, September 23rd. The stock was sold at an average price of $90.00, for a total transaction of $1,800,000.00. Following the completion of the sale, the executive vice president now owns 49,248 shares in the company, valued at approximately $4,432,320. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Reid M. Huber sold 2,715 shares of the business’s stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $109.95, for a total value of $298,514.25. The disclosure for this sale can be found here. Insiders own 13.70% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the company. Fuller & Thaler Asset Management Inc. bought a new position in Incyte Corp. during the second quarter worth $104,000. Acrospire Investment Management LLC boosted its position in Incyte Corp. by 18.2% in the second quarter. Acrospire Investment Management LLC now owns 1,300 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 200 shares in the last quarter. Seven Eight Capital LLC bought a new position in Incyte Corp. during the first quarter worth $113,000. Walleye Trading LLC bought a new position in Incyte Corp. during the second quarter worth $120,000. Finally, Fifth Third Bancorp boosted its position in Incyte Corp. by 16.2% in the second quarter. Fifth Third Bancorp now owns 1,678 shares of the biopharmaceutical company’s stock worth $134,000 after buying an additional 234 shares in the last quarter. Hedge funds and other institutional investors own 92.34% of the company’s stock.

Incyte Corp. Company Profile

Related posts

Leave a Comment